• Sotio Acquires Rights to BOXR Cell Therapy Platform contractpharma
    September 01, 2020
    Sotio, a clinical stage immuno-oncology company owned by PPF Group, has acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and BOXR lead programs to develop novel T cell therapies for the treatment of solid tumors.
PharmaSources Customer Service